Sobi - Swedish Orphan Biovitrum AB (publ)

Sobi – Swedish Orphan Biovitrum AB (publ) is a leading biopharmaceutical company dedicated to developing and delivering innovative therapies for rare diseases. Established in Sweden, Sobi has expanded its reach globally, with a significant presence in the UK. The company focuses on areas such as hematology, immunology, and genetic diseases, aiming to improve the lives of patients with unmet medical needs.

With a strong commitment to research and development, Sobi invests heavily in scientific innovation to create effective treatments. The company collaborates with healthcare professionals, researchers, and patient organizations to ensure that its products meet the highest standards of efficacy and safety.

Core Activities:

• Research and Development: Sobi prioritizes R&D to discover new therapies and improve existing ones.
• Manufacturing: The company ensures high-quality production processes to deliver safe and effective medications.
• Commercialization: Sobi actively markets its products to healthcare providers and patients, ensuring accessibility to vital treatments.

Sobi’s vision is to be a trusted partner in the healthcare community, providing solutions that enhance patient outcomes. The company values integrity, collaboration, and excellence, striving to make a meaningful impact on the lives of those affected by rare diseases.

Through its dedication to innovation and patient care, Sobi continues to lead the way in the biopharmaceutical industry, making significant strides towards a healthier future for all.